Chronic Hepatitis C Clinical Trial
Official title:
An Observational Study Exploring the Utility of the Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic or Acute Viral Infections,
The XN-20, is a full blood count (FBC) analyser with an extended differential counting and
flagging System. The XN-Series' individual channels allow real-time reflex analysis, and uses
a two stage process to classify the white blood count (WBC) sub-populations and detect the
presence of abnormal reactive and malignant cells. In regards to lymphocytes in the
peripheral blood, the machine has the capacity to distinguish activated from non-activated
T-cell subsets using a very small volume of EDTA sample (88uL) (including remnant sample from
a standard full blood count) with results available in 1.5 minutes. It is a fully automated
process and can be considered as an alternative rapid flow cytometry method.
Objective of the SASA study: to investigate the signal pattern of white blood cells assessed
using the XN-20 full blood count platform in patients with untreated viral infections i.e.
HIV, HCV and HBV. The data from the analysis will be reviewed in conjunction with patient's
demographic and clinical disease characteristics with the aim of detecting characteristic
cell populations that can be used in the development of system flags for future studies.
Study design: observational pilot study. Approximately one hundred, participants (25 in each
of group, A to D), will be enrolled at a single clinical site.
Study question: Do participants who have chronic or acute viral infections i.e. untreated
HIV, HIV-HCV with treated HIV and untreated HCV, untreated HCV monoinfection or untreated HBV
monoinfection, have a significant excess of activated lymphocytes as measured by D1+D2 on the
XN WDF channel using the XN-20 analyser?
Objectives:
Primary: To assess whether participants who have chronic or acute viral infections have a
significant excess of activated lymphocytes measured by the Sysmex-XN 20 analyser.
Secondary: To compare, the absolute numbers and percentages of lymphocytes subsets as
measured in the Sysmex-XN 20 analyser to the percentages of these cells when measured using
standard laboratory methods i.e. flow cytometry.
Primary Outcome Measure(s): Percentage of lymphocytes measured in area D1+D2 of the XN WDF
and W1/W2 ratio from the WPC channel.
Secondary Outcome Measure(s ):
1. % lymphocytes in the D1 area of the XN WDF channel;
2. % lymphocytes in the D2 area of the XN WDF channel;
3. % lymphocytes in the D0 area of the XN WDF channel;
4. correlation between CD4+ T-cells (as measured by standard flow cytometry) and the D1+D2
area on the XN WDF channel;
5. correlation between CD8+ T-cells (as measured by standard flow cytometry) and the D1+D2
area on the XN WDF channel;
6. correlation between CD4+ T-cells (as measured by standard flow cytometry) and the W1/W2
area on the XN WPC channel;
7. correlation between CD8+ T-cells (as measured by standard flow cytometry) and the W1/W2
area on the XN WPC channel;
Exploratory:
Association of uncontrolled viral infection and the following as measured on the XN-20
platform
- % of lymphocytes mainly synthesizing antibodies with high fluorescence intensity
(AS-Lymph);
- absolute and % lymphocytes reacting to infection with high fluorescence intensity
(RE-Lymph);
- % reactive monocytes
- Neutrophil reactivity intensity;
- Neutrophil granularity intensity;
- Immature platelet fraction;
- Comparison of the blood film (DI-60 Review) and selected WBC subset read outs from the
XN-20.
- Review of WDF lymphocyte cloud positional information using -
HFLC/LY-X/LY-Y/LY-Z/LY-WX/LY-WY/LY-WZ.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |